The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Pirtobrutinib enhances T-cell anti-tumor immunity in CLL
In this interview, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, discusses the findings of a preclinical study that evaluated the effect of pirtobrutinib, a non-covalent BTK inhibitor, on T-cell immunity in chronic lymphocytic leukemia (CLL). This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Pirtobrutinib is a non-covalent BTK inhibitor, which received quite a bit of publicity at this ASH annual meeting with two different randomized trials reading out and reporting very good efficacy and high tolerability of pirtobrutinib. The aspect that we investigated in this preclinical study is related to the fact that patients with chronic lymphocytic leukemia suffer from immune deficiencies...
Pirtobrutinib is a non-covalent BTK inhibitor, which received quite a bit of publicity at this ASH annual meeting with two different randomized trials reading out and reporting very good efficacy and high tolerability of pirtobrutinib. The aspect that we investigated in this preclinical study is related to the fact that patients with chronic lymphocytic leukemia suffer from immune deficiencies. So, in CLL, immune deficiencies are frequent and infections, unfortunately, are a problem. And this is due to impairment of T-cell function, B-cell function, macrophage function. So, in this preclinical study, we evaluated how pirtobrutinib might affect T-cell immunity in patients with CLL. And we did find interesting findings that pirtobrutinib actually corrected some of the T-cell deficiencies and enhanced cytotoxicity effects of T-cells derived from patients with CLL. So, whether it contributes to pirtobrutinib efficacy in CLL remains to be determined. Whether it also helps correct the immune deficiencies associated with CLL also remains to be determined in clinical trials. However, our results are promising in that it is likely that pirtobrutinib will result in positive effects on patients’ immune system.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
